Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881661 | 0.81 | HTR2A (0.49) | SLC6A2SLC6A4HTR2AHTR2C | |
| SCHEMBL3709944 | 0.79 | HTR2A (0.50) | SLC6A2SLC6A4HTR2AHTR2C | |
| SCHEMBL1956177 | 0.79 | HTR2C (0.43) | HTR2AHTR2C | |
| SCHEMBL25141967 | 0.79 | NOTUM (0.46) | SLC6A2SLC6A4HTR2AHTR2CNOS1 | |
| SCHEMBL29830999 | 0.77 | GPR3 (0.33) | GRM2SLC6A2 | |
| SCHEMBL1077030 | 0.77 | GPR3 (0.33) | GRM2SLC6A2 | |
| SCHEMBL20855264 | 0.76 | SLC6A2 (0.30) | SLC6A2SLC6A4 | |
| SCHEMBL5511626 | 0.75 | GRM2 (0.32) | GRM2SLC6A2SLC6A4 | |
| SCHEMBL30776600 | 0.75 | GRM2 (0.32) | GRM2SLC6A2SLC6A4 | |
| SCHEMBL19617761 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-2351737-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7803830-B2 | 3-amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803830-B2 | 3-amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| EP-1401812-B1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | EP | disclosed |
| CN-1714077-A | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2005-12-28 | — | — | CN | disclosed |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
| US-6790848-B2 | TREATING CENTRAL NERVOUS SYSTEM OR GASTROINTESTINAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-14 | — | — | US | disclosed |
| EP-1326830-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | GRM2 981/4885SLC6A2 3945/4885SLC6A4 3665/4885 |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR3A | GRM2 249/4885SLC6A2 156/4885SLC6A4 23/4885 |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | GRM2 1395/4885SLC6A2 2663/4885SLC6A4 1184/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | GRM2 1455/4885SLC6A2 4011/4885SLC6A4 3640/4885 |
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | GRM2 148/4885SLC6A2 180/4885SLC6A4 34/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | GRM2 185/4885SLC6A2 154/4885SLC6A4 32/4885 |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | DRD2, DRD3, DRD1 | GRM2 538/4885SLC6A2 227/4885SLC6A4 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.